| ￥3300 | |
| Z05115-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 90% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 21 kDa | ||||
| Apparent Molecular Weight | The protein migrates to 25~30 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in 20mM Tris, 0.3M NaCl (pH 8.5). | ||||
| Concentration | Verified by one or more methods from A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -80 °C or below. Avoid repeated freeze-thaw cycles. |
Immobilized CCL5, His-SUMO, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-CCL5 Antibody, hFc Tag with the EC50 of 4.4 ng/ml determined by ELISA. »
CCL5, His-SUMO, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
Immobilized CCL5, His-SUMO, Human, His Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Human CXCL4, His Tag with the EC50 of 1.1μg/ml determined by ELISA. »
Biotinylated Human GPR75 Nanodisc captured on CM5 Chip via Streptavidin can bind CCL5, His-SUMO, Human, His Tag with an affinity constant of 0.77 nM as determined in SPR assay (Biacore T200). »
| Target Background | The CCR5 and the CCL5 ligand have been detected in some hematological malignancies, lymphomas, and a great number of solid tumors, but extensive studies on the role of the CCL5/CCR axis were performed only in a limited number of cancers. |
| Synonyms | MuRantes; SIS-delta; Scya5; Ccl5; D17S136E; eoCP; RANTES; SCYA5; SISd; TCP228; CCL5 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
